FY2024 Earnings Estimate for ISRG Issued By Leerink Partnrs

Intuitive Surgical, Inc. (NASDAQ:ISRG) – Stock analysts at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of Intuitive Surgical in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now forecasts that the medical equipment provider will earn $5.22 per share for the year, down from their prior estimate of $5.23. The consensus estimate for Intuitive Surgical’s current full-year earnings is $5.22 per share. Leerink Partnrs also issued estimates for Intuitive Surgical’s FY2025 earnings at $6.16 EPS.

Other analysts have also issued research reports about the company. Barclays increased their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Mizuho increased their target price on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday. Royal Bank of Canada increased their target price on Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a report on Friday. Piper Sandler restated an “overweight” rating and issued a $538.00 target price (up previously from $495.00) on shares of Intuitive Surgical in a report on Friday. Finally, Truist Financial increased their price objective on Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a report on Monday, October 14th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $513.74.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $521.15 on Friday. The stock has a fifty day moving average of $483.85 and a 200-day moving average of $438.17. The company has a market capitalization of $184.85 billion, a PE ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical has a one year low of $254.85 and a one year high of $523.34.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the firm earned $1.18 EPS. The company’s quarterly revenue was up 14.5% compared to the same quarter last year.

Insider Activity

In other news, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the sale, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the sale, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Intuitive Surgical

Several hedge funds have recently made changes to their positions in ISRG. Capital Research Global Investors bought a new stake in shares of Intuitive Surgical in the first quarter valued at about $374,390,000. Vanguard Group Inc. lifted its stake in shares of Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Intuitive Surgical by 51.2% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock valued at $356,524,000 after buying an additional 302,382 shares during the period. Strategic Financial Concepts LLC lifted its stake in shares of Intuitive Surgical by 40,221.4% in the second quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock valued at $1,184,000 after buying an additional 265,461 shares during the period. Finally, GQG Partners LLC bought a new position in Intuitive Surgical during the first quarter worth about $99,523,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.